$-0.07
(Market cap
$0 Mln
Recently Viewed
Clear AllMarket cap
$0 Mln
Revenue (TTM)
$20 Mln
P/E Ratio
--
P/B Ratio
5.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$36 Mln
ROE
0 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.9
Debt to Equity
0
Book Value
$-0.3
EPS
$-0.1
Face value
--
Shares outstanding
44,574,021
CFO
$-133.11 Mln
EBITDA
$-119.18 Mln
Net Profit
$-187.73 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aridis Pharmaceuticals (ARDS)
| -- | -- | -- | -- | -90.5 | -87.2 | -- |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|
|
Aridis Pharmaceuticals (ARDS)
| -94.1 | -49.4 | -61.6 | 36.4 | -59.9 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aridis Pharmaceuticals (ARDS)
|
0.0 | 0.0 | 20.1 | -1.1 | -3.3 | -- | -- | 5.4 |
| 73.9 | 10,349.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.2 | 18.2 | |
| 65.3 | 8,115.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.9 | 11,415.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.2 | 5.3 | |
| 88.9 | 11,662.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 65.4 | 7,743.5 | 1,396.6 | 316.9 | 59.8 | 153.6 | 26 | 161.6 | |
| 512.4 | 11,754.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.5 | |
| 410.5 | 11,724.9 | 2,678.3 | 460.4 | 21.1 | 103.2 | 25.9 | 19.6 | |
| 104.5 | 8,215.5 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 344.8 | 9,603.5 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully... human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California. Read more
Founder & Executive Chairman
Dr. Eric J. Patzer Ph.D.
Founder & Executive Chairman
Dr. Eric J. Patzer Ph.D.
Headquarters
Los Gatos, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Aridis Pharmaceuticals Inc (ARDS) is $0.00 (NASDAQ) as of 24-Apr-2026 09:30 EDT. Aridis Pharmaceuticals Inc (ARDS) has given a return of -90.46% in the last 3 years.
Since, TTM earnings of Aridis Pharmaceuticals Inc (ARDS) is negative, P/E ratio is not available.
The P/B ratio of Aridis Pharmaceuticals Inc (ARDS) is 5.40 times as on 24-Apr-2026, a 18 premium to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-1.04
|
-1.32
|
|
2021
|
-0.80
|
-2.58
|
|
2020
|
-2.69
|
-6.92
|
|
2019
|
-1.37
|
10.91
|
|
2018
|
-4.07
|
3.42
|
The 52-week high and low of Aridis Pharmaceuticals Inc (ARDS) are Rs 0.00 and Rs 0.00 as of 26-Apr-2026.
Aridis Pharmaceuticals Inc (ARDS) has a market capitalisation of $ 0 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Aridis Pharmaceuticals Inc (ARDS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.